when prostate-specific antigen (PSA) screening became widespread. This decrease is likely attributable to 2 factors. First, after more than 3 decades of widespread PSA screening to detect prostate cancer, there are few men with high PSA levels that haven’t already been diagnosed. Second, and ...
Of the 220,000 new cases of prostate cancer diagnosed each year, up to 75% are treated by local therapy. Some 50,000 to 60,000 of these patients experience biochemical failure, or biochemical re...
For 20 years, the message has been the same: Get a PSA test every year or two, detect prostate cancer early -- and save your life. Dr. Michael Lefevre helped lead the panel that said the message was wrong. "The problem is that in contrast to the small benefits, a significant n...
The aim of screening for prostate cancer is to detect malignancy at an early and potentially treatable stage, thereby increasing the chance of cure. Although serum PSA has been used as a screening test for prostate cancer for over 20 years, the practice is controversial. As a screening test ...
Prostate Cancer: Does PSA screening do more harm than good?doi:10.1038/nrurol.2009.63FarleySuzanne J.OAINature Reviews Urology
The PLCO trial was conceived in the early 1990’s soon after the wave of enthusiasm brought by the belief that prostate-specific antigen (PSA) screening could save the lives of men with prostate cancer. In consequence, the PLCO did not have the ideal counterfactual for a control group. ...
First, after more than 3 decades of widespread PSA screening to detect prostate cancer, there are few men with high PSA levels that haven't already been diagnosed. Second, and perhaps more important, PSA screening is now becoming less common. In 2008, the US Preventive Services Task Force (...
Furthermore, it has been reported that some patients with PSA levels less than 4 did have prostate cancer. It appears that rapidity at which the PSA is rising is a better predictor of aggressive cancer. For these reasons, the use of PSA for prostate cancer screening is a controversial issue...
In terms of biological response 11 of 20 patients (55%) receiving prednisolone and 10 of 20 (50%) receiving flutamide exhibited prostate specific antigen (PSA) suppression. Average minimum PSA was 54 and 52% of the initial PSA in patients receiving prednisolone and flutamide, respectively. There...
Men diagnosed with what has classically been termed “intermediate-risk” prostate cancer (PCa)—based on Gleason score 7, prostate-specific antigen (PSA) 10−20 ng/mL, and clinical stage T2b or 2c disease—have highly variable clinical behavior and prognosis and are considered a broad, he...